Alembic Pharmaceuticals Limited (Alembic) has announced in a stock exchange filing that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Selexipag for Injection, 1,800 mcg/vial. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Uptravi® for Injection, 1,800 …